Results 81 to 90 of about 5,478,695 (241)

SPRED2 Negatively Regulates CD8+ T Cell‐Mediated Antitumor Immunity in Breast Cancer

Advanced Science, EarlyView.
Sprouty‑related EVH1 domain containing 2 (SPRED2) restrains Ras/Raf/ERK signaling in CD8+ T cells. Host SPRED2 deficiency enhances T‐cell survival, cytotoxicity, and memory‐like phenotypes, reducing primary tumor growth and endpoint lung metastatic burden in breast cancer models.
Miao Tian, Teizo Yoshimura, Kun Zhao, Chunning Li, Tong Gao, Ziyi Wang, Masayoshi Fujisawa, Toshiaki Ohara, Akihiro Matsukawa   +8 more
wiley   +1 more source

2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies

Journal of Hematology & Oncology, 2019
Background Chimeric antigen receptor engineered T cells (CAR-T) have demonstrated extraordinary efficacy in B cell malignancy therapy and have been approved by the US Food and Drug Administration for diffuse large B cell lymphoma and acute B lymphocytic ...
Yingxi Xu, Qian Liu, Mengjun Zhong, Zhenzhen Wang, Zhaoqi Chen, Yu Zhang, Haiyan Xing, Zheng Tian, Kejing Tang, Xiaolong Liao, Qing Rao, Min Wang, Jianxiang Wang   +12 more
doaj   +1 more source

A Multi‐Targeting Chimeric Antigen Receptor‐T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non‐Small Cell Lung Cancer

Advanced Science, EarlyView.
A dual‐transmembrane Bicephali CAR‐T platform simultaneously targets CD276 and NKG2D ligands to address antigen heterogeneity in non‐small cell lung cancer. By improving immune synapse formation, mitochondrial fitness, antioxidant capacity, and stem‐like persistence, this design enhances durable tumor control and provides a versatile strategy to ...
Lina Wang, Yanlei Zhang, Shuixiu Peng, Chenchen Hou, Huaqi Guo, Tianyu Zhou, Alex H. Chang, Lifeng Yan, Weining Xiong   +8 more
wiley   +1 more source

Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment

Cells
CAR-T cell therapy is a promising method of cancer treatment, but it has some disadvantages. These disadvantages have led scientists to explore the use of safer CAR-NK cells and new genetic modifications in order to improve the effectiveness of CAR cells.
Tatiana Budagova, Anna Efremova, Margarita Maiak, Dmitry Goldshtein   +3 more
doaj   +1 more source

Immune Biomarkers of Islet Transplant Rejection Revealed by Synthetic Immunological Niche

Advanced Science, EarlyView.
A subcutaneous synthetic immunological niche (IN) enables serial, minimally invasive monitoring of immune responses after islet transplantation. Flow cytometry and transcriptomic profiling of the IN reveal immune‐cell programs associated with graft acceptance and distinct types of rejection.
Jyotirmoy Roy, Abdalmonam Jadou Nejma, Mohammad Tarique, Amod Talekar, Shengli Wu, Brianna Ha, Yifei Jiang, Esma S. Yolcu, Lonnie D. Shea   +8 more
wiley   +1 more source

CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon

Blood Science, 2019
Abstract Chimeric antigen receptor (CAR)-T-cell therapy has achieved significant success in the treatment of hematologic malignancies. However, treatment-related toxicity and side effects remain the major drawbacks. As an important effector cell in innate immunity, natural killer (NK) cells exert strong antitumor functions and ...
Kai-lin Xu, Hai Cheng
openaire   +3 more sources

Fc‐Dependent Targeting of the GAS6–MERTK Axis With Monoclonal and Bispecific Antibodies Overcomes Drug Resistance Across EGFR Mutations in Exons 19, 20, and 21

Advanced Science, EarlyView.
EGFR mutations drive a substantial fraction of non‐small cell lung cancers (NSCLC) and are effectively targeted by tyrosine kinase inhibitors (TKIs), including osimertinib. However, resistance inevitably develops through secondary mutations and compensatory receptor activation, including the GAS6 receptor MERTK.
Suvendu Giri, Boobash Raj Selvadurai, Nitin Gupta, Arturo Simoni‐Nieves, Alessandro Genna, Moshit Lindzen, Rishita Chatterjee, Marieke Van Daele, Deepthi Ramesh Kumar, Mirie Zerbib, Roni Oren, Isabelle Sophie Meijer, Elisabeth Franziska Wippich, Yahel Avraham, Rony Dahan, Yuya Haga, Laura E. Kilpatrick, Simon Platt, Stephen J. Hill, Lipika R. Pal, Eytan Ruppin, Yasuo Tsutsumi, Eliane Hadas Yardeni, Muhammad Abu Ahmad, Olga Radinsky, Donatella Romaniello, Mattia Lauriola, Angel Porgador, Yosef Yarden   +28 more
wiley   +1 more source

CAR-NK cell therapy: a potential antiviral platform

Science Bulletin
Viral infections persist as a significant cause of morbidity and mortality worldwide. Conventional therapeutic approaches often fall short in fully eliminating viral infections, primarily due to the emergence of drug resistance. Natural killer (NK) cells, one of the important members of the innate immune system, possess potent immunosurveillance and ...
Ming-Hao, Lin, Li-Juan, Hu, Jeffrey S, Miller, Xiao-Jun, Huang, Xiang-Yu, Zhao   +4 more
openaire   +2 more sources

HADHA K406 Lactylation Regulates Metabolic Reprogramming and Suppresses Immune Responses in Gastric Cancer

Advanced Science, EarlyView.
HADHA K406 lactylation fuels fatty acid β‐oxidation and HMGCR‐dependent cholesterol biosynthesis, fostering immunosuppressive MDSCs and exhausted CD8+ T cells in gastric cancer. Loss of this modification blocks cholesterol production, remodels the tumor microenvironment, and tumor growth is suppressed via combined inhibition of HMGCR and LDHA ...
Maoxiao Feng, Qinlian Jiao, Jiankang Zhu, Yidan Ren, Xiaoyu Teng, Xin Su, Zigan Li, Yuxuan Cai, Xiaoyan Liu, Yunshan Wang, Guangyong Zhang   +10 more
wiley   +1 more source

Scalable process development of NK and CAR-NK expansion in a closed bioreactor

Frontiers in Immunology
Production of large amounts of functional NK and CAR-NK cells represents one of the bottlenecks for NK-based immunotherapy. In this study, we developed a large-scale, reliable, and practicable NK and CAR-NK production using G-Rex 100M bioreactors, which ...
Xuening Wang, Maeve Elizabeth Byrne, Chang Liu, Minh Tuyet Ma, Dongfang Liu, Dongfang Liu   +5 more
doaj   +1 more source